2020
Effect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children
Gore‐Langton G, Cairns M, Compaoré Y, Sagara I, Kuepfer I, Zongo I, de Wit M, Barry A, Diarra M, Tapily A, Coumare S, Thera I, Nikiema F, Yerbanga R, Guissou R, Tinto H, Dicko A, Chandramohan D, Greenwood B, Ouedraogo J. Effect of adding azithromycin to the antimalarials used for seasonal malaria chemoprevention on the nutritional status of African children. Tropical Medicine And International Health 2020, 25: 740-750. PMID: 32166877, DOI: 10.1111/tmi.13390.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionMalaria transmission seasonMalaria chemopreventionNutritional statusTransmission seasonTreatment armsAddition of azithromycinEffect of azithromycinNutritional status indicatorsCross-sectional surveyHospital admissionRecent trialsMass administrationAnthropometric measurementsChronic malnutritionAzithromycinAfrican childrenChemopreventionNutritional outcomesBurkina FasoContinuous outcomesStudy periodMode of actionProtocol analysisYoung childrenIn vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso
Lingani M, Bonkian L, Yerbanga I, Kazienga A, Valéa I, Sorgho H, Ouédraogo J, Mens P, Schallig H, Ravinetto R, d’Alessandro U, Tinto H. In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal 2020, 19: 8. PMID: 31906948, PMCID: PMC6945612, DOI: 10.1186/s12936-019-3089-z.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAmodiaquineAntimalarialsArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateBurkina FasoChildChild, PreschoolDrug CombinationsDrug Therapy, CombinationFemaleHumansInfantInhibitory Concentration 50LumefantrineMalaria, FalciparumMaleMass Drug AdministrationPlasmodium falciparumTreatment FailureTreatment OutcomeConceptsFirst-line treatmentArtemether-lumefantrineUncomplicated malariaFalciparum malariaTreatment failureOverall adverse event incidenceUncomplicated Plasmodium falciparum malariaEx vivo efficacyUnadjusted cure rateAdverse event incidenceUncomplicated falciparum malariaPlasmodium falciparum malariaP. falciparum susceptibilityMalaria-endemic areasEx vivo susceptibilityMass drug administrationP. falciparum isolatesEx vivo analysisAL armASAQ armOpen labelPrimary endpointRecurrent parasitaemiaEvent incidenceTreatment arms
2014
Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso
Somé A, Zongo I, Compaoré Y, Sakandé S, Nosten F, Ouédraogo J, Rosenthal P. Selection of Drug Resistance-Mediating Plasmodium falciparum Genetic Polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrobial Agents And Chemotherapy 2014, 58: 3660-3665. PMID: 24733476, PMCID: PMC4068591, DOI: 10.1128/aac.02406-14.Peer-Reviewed Original ResearchConceptsSeasonal malaria chemopreventionAQ/SPMalaria chemopreventionSingle nucleotide polymorphismsP. falciparum crtPfcrt 76TResistance-mediating polymorphismsMalaria control measuresPCR-positive samplesMonthly DPPfdhfr 108NPfdhfr 51IPfmdr1 86YSulfadoxine-pyrimethamineTreatment armsDevelopment of resistanceTransmission seasonControl groupP. falciparumSNP prevalenceGenetic polymorphismsRegular useAntifolate antimalarialsMonthsBurkina Faso